Summary
This 2024 narrative review in Trends in Pharmacological Sciences examines clinical biomarkers relevant to ulcerative colitis diagnosis, prognosis, and treatment monitoring, alongside emerging pharmacological approaches to disease management. The authors synthesise current evidence on measurable indicators of disease activity and identify novel therapeutic targets as suggested by recent literature. The work appears intended for a pharmacological audience seeking updated knowledge on UC management within a precision medicine framework.
Regional applicability
Findings on clinical biomarkers and therapeutic targets are applicable to UK clinical practice and NHS prescribing guidance, subject to validation in UK patient populations and alignment with NICE appraisal processes for new treatments. The review may inform gastroenterology and primary care management of inflammatory bowel disease in UK settings.
Key measures
Clinical biomarkers (as suggested by title); therapeutic targets and treatment efficacy measures (specific metrics inferred from journal and publication year)
Outcomes reported
The paper reviews clinical biomarkers associated with ulcerative colitis disease activity and progression, and evaluates emerging therapeutic targets and treatment modalities. It synthesises current evidence on diagnostic and prognostic indicators alongside novel pharmacological interventions.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.